Literature DB >> 17902173

Enhancement of gene transfer using YIGSR analog of Tat-derived peptide.

Amer F Alhaj Saleh1, Harmesh S Aojula, Alain Pluen.   

Abstract

Cell penetrating peptide based gene carriers are notably known for low level of gene transfer. To remedy this, as laminin receptor (LR) has been previously linked to tumor metastasis, the LR-binding domain (YIGSR) as well as a scrambled sequence (SGIYR) were added to Tat-derived peptide sequence (YIGSR-Tat and SGIYR-Tat respectively). Peptides cellular uptake was assessed with high-LR (HT1080) and low-LR (HT29) cell lines by flow cytometry. Their ability to form complexes with DNA was examined using YOPRO-1 fluorescence assay and their transfection efficiencies evaluated using a luciferase reporter gene assay. DNA complexes were formed at (+/-) charge ratios as low as 2:1. While no conclusion could be drawn on the effect of YIGSR sequence on peptides uptake in both cell lines, a significant improvement in gene transfection in HT1080 cells was achieved using YIGSR-Tat compared to Tat and SGIYR-Tat. Additionally this increased efficiency was inhibited by excess free YIGSR. No significant difference in transfection efficiency was observed between Tat, SGIYR-Tat and YIGSR-Tat based complexes in HT29 cells. These studies demonstrate that attachment of receptor-binding ligand (YIGSR) to Tat-derived peptide can improve the efficiency of gene transfer in LR-positive cells (HT1080).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17902173     DOI: 10.1002/bip.20854

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  2 in total

1.  Calcium condensation of DNA complexed with cell-penetrating peptides offers efficient, noncytotoxic gene delivery.

Authors:  Abdulgader A Baoum; Cory Berkland
Journal:  J Pharm Sci       Date:  2010-12-13       Impact factor: 3.534

2.  Polyarginine molecular weight determines transfection efficiency of calcium condensed complexes.

Authors:  Nabil A Alhakamy; Cory J Berkland
Journal:  Mol Pharm       Date:  2013-04-15       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.